

CURRICULUM VITAE

Richard A. Galbraith, M.D., Ph.D., F.R.C.P.

Date of birth: October 6, 1950

Citizenship: United States

Office: Offices of the Provost, the Dean of the College of Medicine and the Department of
Medicine
University of Vermont, Burlington, Vermont 05405
Telephone: 802-656-0814
FAX: 802-656-4584
E-Mail: richard.galbraith@uvm.edu

EDUCATION:

1963-1968 Hurstpierpoint College, Sussex, England
1969-1971 King's College, University of London, England
1971-1974 King's College Hospital Medical School, London (Medical Bachelor, Bachelor of Surgery; M.D.)
1973 Tropical Medicine, Nigeria, W. Africa
1978-1981 Graduate School, Medical University of South Carolina, Charleston, SC
(Ph.D. in Molecular and Cellular Biology and Pathobiology)

POST-GRADUATE TRAINING:

1975-1976 Internship: House Officer, Pediatrics, King's College Hospital
House Officer, General Surgery, St. Nicholas Hospital, London
1976-1977 Residency, Internal Medicine, St. Nicholas Hospital, London
1977-1978 Medical Registrar, Internal Medicine, St. Nicholas Hospital, London
1978-1980 Fellow in Endocrinology, Metabolism and Nutrition, Medical University of South Carolina
(M.U.S.C.), Charleston, S.C.

LICENSURE AND CERTIFICATION

- 1975 General Medical Council of England; Full Licensure
- 1975 Educational Commission for Foreign Medical Graduates (ECFMG), U.S.A.
- 1977 Membership of the Royal College of Physicians (English Boards in Internal Medicine)
- 1980 Federal Licensing Examination, (FLEX), U.S.A.
- 1980 Board Eligible in Internal Medicine and Subspecialty Board Eligible in Endocrinology.
- 1981-1983 South Carolina Full Licensure
- 1983-1995 New York Full Licensure
- 1992 Diplomat of The American Board of Medical Management, American College of Physician Executives
- 1995-present Vermont Full Licensure #042-0009049

PROFESSIONAL POSITIONS:

- 1980-1983 Attending Physician, M.U.S.C., Charleston Memorial Hospital and Charleston Veterans Administration Hospital, Charleston, S.C.
- 1983-1988 Associate Physician, Rockefeller University Hospital, New York, N.Y.
- 1984-1995 Attending Physician, New York Hospital, New York, N.Y.
- 1988-1995 Physician, Rockefeller University Hospital, New York, N.Y.
- 1995-present Attending Physician, Fletcher Allen Health Care, Burlington, VT.
- 1995-present Chief of the Division of Clinical Pharmacology, Department of Medicine, UVM/Fletcher Allen Health Care, Burlington, VT.

ACADEMIC APPOINTMENTS:

- 1980-1981 Instructor in Medicine, Medical University of South Carolina, Charleston, SC
- 1981-1983 Assistant Professor in Medicine, M.U.S.C.
Graduate School Faculty, M.U.S.C.
- 1983-1990 Assistant Professor, Rockefeller University, New York, NY
- 1984-1990 Adjunct Assistant Professor of Medicine, Cornell University Medical College, New York, NY
- 1990-1995 Associate Professor, Rockefeller University, New York, NY

- 1990-1995 Adjunct Associate Professor of Medicine, Cornell University Medical College, New York, NY
- 1995-present Professor of Medicine, University of Vermont, Burlington, VT
- 1995-present Graduate School Faculty, University of Vermont, Burlington, VT

ACADEMIC HONORS AND FELLOWSHIPS:

- 1980 Winner Post-Doctoral Research Competition, M.U.S.C.
- 1982-1985 Hartford Foundation Research Fellowship Award
- 1986-1991 Surdna Foundation Fellow
- 1992 Fellow, The Royal College of Physicians
- 2003 Member, Vermont Academy of Science and Engineering

ADMINISTRATIVE POSITIONS:

- 1988-1995 Program Director, Rockefeller University Hospital, General Clinical Research Center (GCRC), New York, N.Y.

Responsible for grant administration and scientific leadership of the GCRC at Rockefeller University Hospital. GCRC inpatient utilization averaged 7,000 annually and outpatient utilization averaged 6,000 annually; all patients were participating in research studies. The Program Director (PD) was responsible for running all aspects of grant M01-RR00102 with total costs of \$6 million annually. In 1993 the PD was responsible for assembling, writing and successfully obtaining funding for the GCRC competitive renewal grant (\$31 million over 5 years) from the NIH.

- 1990-1995 Medical Director and Administrative Director, Rockefeller University Hospital, New York, N.Y.

Hospital administrator of an 8-story stand-alone research building on the Rockefeller University Campus. Two of the floors were involved in GCRC inpatient care, one floor for GCRC outpatient care, one floor for administration, and the remaining four floors were home to several clinical and basic research laboratories. Operating budget of the hospital (excluding the operation of the research wet labs) was \$8 million per year. The hospital administrator was responsible for professional and auxiliary staff, budgeting and financial control, credentialing of medical staff and medical staff affairs, regulatory and granting agency relations, physical plant and safety, quality assurance, JCAHO certification, the University-wide Employee Health Service, and external contracting for radiology services from the New York Hospital and for laboratory services from the Memorial Sloan Kettering Hospital. The Medical Director and Administrator reported directly to the Executive Vice President of the University.

1995-2012 Program Director of the University of Vermont General Clinical Research Center, Burlington, VT.

The Program Director was responsible for running all aspects of the inpatient and outpatient research operations on the floor, as well as administering and obtaining ongoing NIH funding to operate the Center. The grant (M01 RR00109) was successfully renewed on three occasions by the PD (1997-2000, \$7.36 million; 2000-2005, \$12.5 million; 2006-2011, \$11.86 million). The PD was also responsible for upgrading the equipment and physical plant for mass spectrometry, research nutrition kitchen, human physiology, laboratory and research IT. Recently, the PD was responsible for planning and design of new CRC facilities on Shepardson 2 in Fletcher Allen Health Care.

1995-2012 Associate Dean, Patient Oriented Research, College of Medicine, University of Vermont, Burlington, VT.

This position was created in 1995 expressly to widen the scope of the GCRC Program Director to include other responsibilities spanning the entire spectrum of research involving human subjects. Thus, the purview of the Associate Dean included early translational studies such as those performed on the GCRC, clinical trials, the creation of a new Office of Patient Oriented Research to assist medical practitioners in refining and answering clinical questions with rigorous scientific methodology, and community-based epidemiology, health care outcomes research, health care economics research, and various statewide initiatives. Some specific examples of projects undertaken by the Associate Dean for Patient Oriented Research are as follows:

- The Office of Patient Oriented Research became operational in 1997 following the hiring of Robert Ross, Ph.D. as its director. The Office was responsible for advocacy, fund raising and assisting in all aspects of investigator-initiated clinical research. Services of the office included initial consultations to define and refine research questions, and referrals to expert cores wherein professionals donated their time in the fields of biostatistics, epidemiology, clinical trials design, health care economics and informatics. The Office obtained institutional funding to set up a pilot program wherein \$100,000 was disbursed annually to enable faculty to obtain preliminary data. The program was competitive with peer review from a scientific advisory committee and in the first two years of its operation, the \$100,000 annual investment from Fletcher Allen Health Care resulted in 26 publications from 16 awardees and a financial return from extramural research funding of \$2.9 million and \$2.8 million respectively. So successful was this program that it was used as a model on which the National Center for Research Resources at NIH fashioned its Clinical Research Feasibility Funds Program that became operational through additional federal funding to the General Clinical Research Centers. In many ways, this program was a harbinger of the Clinical and Translational Research Awards (CTSA) era.
- The Vermont Diabetes Initiative. This effort was organized by the Associate Dean for Patient Oriented Research by bringing together numerous experts on diabetes, both from the University of Vermont, and from the Vermont State Department of Health, the Vermont Program for Quality in Health Care and certain experts from the Centers for Disease Control. After extensive deliberations and planning, which took over a year, the Associate Dean approached and elicited the interest and help of a group called the Northeast Clinical Laboratory Alliance. This group, which was comprised of all of the

laboratory managers from all the hospitals in Vermont, had recently formed and was meeting regularly to discuss quality control and management issues. They became, however, very receptive to the idea of participating in a research project, the gist of which was to collect all of the hemoglobin A1Cs (an index of the adequacy of diabetic blood sugar control) performed on all the patients in the State of Vermont during a given month. This data was then cross-indexed and correlated to an ICD9 discharge diagnosis of diabetes to be sure that the hemoglobin A1Cs being collected were for established diabetics and not being used for screening purposes in normal individuals. This initiative was expanded and developed by Dr. Littenberg into new investigations with over \$2 million of extramural funding. Later, a more comprehensive system based on these initial approaches was funded by the NIH and led to a UVM patent.

- The Musculoskeletal Research Group. Enormous strength exists in the area of musculoskeletal research at the University of Vermont, but the research is spread across multiple clinical and basic departments and in many cases, individuals operating at one end of the spectrum have no idea of the work or even existence of those operating at the other end. Another interdisciplinary group was convened by the Associate Dean that met regularly, exchanged ideas, had an ongoing seminar series and resulted in successful competition for NIH funding for \$100,000 P20 Planning Grant award.
- Residency Research Training. Many of the residency programs at Fletcher Allen Health Care require incumbents to undertake a period of scholarly activity. This resulted in a smorgasbord of small clinical research courses being offered by individual departments. The Associate Dean for Patient Oriented Research convened a multidisciplinary group of investigators interested in teaching methodological approaches to clinical investigation. This multidisciplinary group planned and offered a combined introduction to clinical research course for all interns and residents at the institution, as well as being an optional course for medical students. This program was subsequently folded into the more comprehensive training modules offered by Dr. Littenberg. K30 funding from the NIH was obtained by Dr. Littenberg to support this program, which has since been integrated into the Center for Clinical and Translational Science.

1999-2005 The Clinical Research Meetings; Liaison to the National Alliance.

A coalition of philanthropies interested in Clinical Research met in the late 90s (the Burroughs Wellcome Fund, the Doris Duke Charitable Foundation, the Robert Wood Johnson Foundation, the Damon Runyan-Walter Winchell Foundation and the Juvenile Diabetes Research Foundation) and subsequently met again with various officers of the Clinical Research Societies. From that meeting emerged the notion that the various stakeholders in clinical research could achieve more by collaboration on several fronts. One of these was the possibility of combining the scientific components of the various society meetings without losing the identity, individuality and tradition of each separate society. The position of Liaison to this Clinical Alliance was to encourage and invite participation from the clinical research societies in a national forum, and to request, justify and administer the funding (\$638,513) for that forum provided through the auspices of the various philanthropies. A major theme of the meetings has become the focus on trainees in clinical investigation. The General Clinical Research Centers Program Directors Association (GCRC PDA) and the Association for Patient Oriented Research (APOR) met together in 2000. The first officially designated Clinical Research Meeting in 2001 was sponsored by the GCRC PDA, APOR and the American Federation of Clinical Research (AFCR); the second, in

2002, saw an increase in attendance, especially of trainees; the third, in 2003, saw the further addition of the Association for Clinical Research Training (ACRT); the fourth in March 2004, saw the addition of the Central Society for Clinical Research and was held in partial conjunction with the American Association of Physicians/ the American Society for Clinical Investigation meetings. In addition, the funding base grew with the addition of the Howard Hughes Medical Institute. After the last meeting in 2005, it was decided to suspend meetings until there was greater clarity concerning the GCRC meetings (which ended in 2006) and future CTSA meetings. Currently, APOR, AFRCR, ACRT, the Society for Clinical and Translational Science and the Clinical Research Forum all meet concurrently.

2007-present Director, Center for Clinical and Translational Science at UVM.

The Director was responsible for explaining the concepts behind and for building the consensus for a CTSA application that included all eight Colleges at UVM and the affiliated teaching hospital, Fletcher Allen Health Care. A full application based on the specifically-created Matrix Center Model was submitted in January 2013 (\$19,918,000), but was not funded.

The CCTS, housed in the Given Courtyard, consists of two tenure-track Bioinformaticists, two programmers, a systems analyst and two graduate students; a tenure-track Health Economist, a programmer and a research health economist; a tenured Director of the education group of seven faculty who supervise the Graduate Certificate, the MS and PhD in CCTS; and the Director of Translational Technologies who runs the Laboratory for Biochemistry Research.

2012-2014 Associate Dean for Research, College of Medicine, University of Vermont

In 2012, Dr. Ira Bernstein, Senior Associate Dean for Research at the College of Medicine, was also appointed Chair of the Department of Obstetrics, Gynecology and Reproductive Services. Approximately 2/3 of his responsibilities as Senior Associate Dean for Research were transferred to the Associate Dean for Research. These included managing the:

- College of Medicine Institutional Grant Program/Bridge Funding
- Medical Student Research Fellowships
- FAHC Physician Orientations
- UVM/FAHC Community Rounds
- IT Support
- Compliance
- Facility security and repairs
- Space allocation
- Graduate Program oversight
- Core laboratories (including animal facilities)
- Graduate Alumni
- Vermont Cancer Center Liaison

2014-present Interim Senior Associate Dean for Research, College of Medicine, University of Vermont.

In 2014, the Associate Dean for Research was appointed as the Interim Senior Associate Dean for Research. In addition to the responsibilities include those listed above for the

Associate Dean for Research, the following additional responsibilities were added:

- Strategic and operational planning
- Grant sign off
- Office of the Vice President for Research Liaison
- Member, FAHC Research and Education Committee
- Development fund allocation
- Vermont Genetic Network Steering Committee
- Dean's Tax allocations to Departments
- Manage research equipment purchase
- Joint UVM/Vermont Department of Health BSL3/ABSL3 facilities oversight

TEACHING EXPERIENCE:

- 1977-1978 Membership of The Royal College of Physicians examination preparatory course for Medical Interns and Residents, St. Nicholas Hospital, London
- 1978-1980 Clinical Endocrinology for Interns and Residents; and Introduction to Physical Diagnosis for Medical Students, M.U.S.C., Charleston, S.C.
- 1980-1981 Instructor in Medicine, M.U.S.C., Charleston, S.C.
- 1981-1983 Graduate School Faculty, M.U.S.C., Charleston, S.C.
- 1984-1995 Co-Attending Teaching Physician, N.Y. Hospital, N.Y.
- 1984-1988 Question writer in Biochemistry for the Kaplan Educational Courses, N.Y.
- 1986-1995 Introduction to Clinical Research for M.D. Ph.D. Students, Rockefeller University/Cornell Medical School/Sloan Kettering Tri-Institutional Ph.D. Program, NY
- 1988-1995 Director, Introduction to Clinical Research for M.D. Ph.D. Students, Rockefeller University/Cornell Medical School/Sloan Kettering Tri-Institutional Ph.D. Program, NY
- 1989-1995 Preceptor in Advanced Biochemistry for Graduate Students, Rockefeller University, N.Y.
- 1995-1999 Health Talk. A clinical /research televideoconference discussion with experts for public education in the State of Vermont.
- 1995-present Introduction to Patient Oriented Research for Medical Students, UVM.
- 1995-present Graduate School Faculty, UVM
- 1996-2010 HELiX student preceptor, UVM
- 1999 Community Medical School for public education about medicine and research in Vermont.
- 2005-2007 Lecturer in Medical School Metabolism Courses.

STUDENTS:

1980-1981 Charles Burant: Graduate Student, MUSC
 1993 Rachel Boni: Exchange Post-doc from Switzerland, Rockefeller University
 1994 Michael Turner: Pew Fellow, Rockefeller University
 1997 Lloyd Fisher: HELiX Program, University of Vermont
 1997-2000 Cynthia Sites, M.D., NCRR GCRC CAP, University of Vermont
 1997-2000 Ernesto Garcia-Rubi, M.D., NCRR GCRC MCAP, University of Vermont
 1998 Susannah Hill: HELiX Program, University of Vermont
 1999/2000 Caralynn Maille: Honors Thesis, University of Vermont
 2000/2001 Sarah Ethier: Honors Thesis, University of Vermont
 2001/2002 Elizabeth Young: Honors Thesis, University of Vermont
 2002/2003 Molly Robinson: Honors Thesis, University of Vermont
 2003/2004 Masaru Furukawa: HELIX Program, University of Vermont
 2006 Preceptor to 4 students from the School of Business Administration

EDITORIAL AND SCIENTIFIC REVIEW POSITIONS:

1985-present Ad Hoc Reviewer, Pharmacology, Hepatology, European Journal of Clinical Investigation, Pediatrics, Pediatric Research, Journal of Coronary Artery Disease
 1997-present Reviewer, Clinical Therapeutics and Medical Economics Publications
 1997-2000 Member, International Wellcome Trust Clinical Research Facility Review Committee
 1998-present Reviewer, The American Journal of Clinical Nutrition
 2001 Member, Search Committee for the Director of the Division of Clinical Research NCRR, NIH
 2012 NCRR K12 Review Committee, NIH
 2010-present NIH Director's Pioneer Awards Review Committee

SPECIAL APPOINTMENTS:

Appointments in New York:

1984-1995 Member, Institutional Review Board for Human Research, Rockefeller University.
 1988-1992 Member, Physical Plant Advisory Committee and Safety Committee, Rockefeller University.
 1988-1993 Chairman, Utilization Review and Quality Assurance Committees, Rockefeller University Hospital.
 1988-1995 Member, Clinical Committee, Isotope Human Use Subcommittee, Pharmacy Committee, Infection Control Committee and Medical Credentials Committee, Rockefeller University Hospital.

Appointments in Vermont:

1995	Search Committee for Oncology Chief, Fletcher Allen Health Care.
1995-1996	Search Committee for Pharmacology Chair, College of Medicine, University of Vermont.
1995-1996	Review Committee for Surgery Chair, College of Medicine, University of Vermont.
1995-1996	Strategic Research Committee, College of Medicine, University of Vermont.
1995-1997	Integration Committee, College of Medicine, University of Vermont.
1995-1997	LCME Subcommittee on Objectives, College of Medicine, University of Vermont.
1996	JCAHO Ethics Team, Fletcher Allen Health Care.
1996-1998	Research and Education Committee, College of Medicine and Fletcher Allen Health Care.
1996-2000	Statewide Evaluation Committee for the Vermont Coalition of Clinics for the Uninsured.
1997-1998	Chair, Redesign Research Core, Fletcher Allen Health Care.
1997	Search Committee for Chief of Medical Genetics, Fletcher Allen Health Care.
1998-1999	Search Committee for Chief of General Internal Medicine, Fletcher Allen Health Care.
1999-2012	College of Medicine Admissions Committee, University of Vermont.
2000-2010	Member, M.D., Ph.D. Program Committee, University of Vermont.
2000-2002	Member, Subcommittee for Redesign of College of Medicine Admissions Committee Criteria and Procedures, University of Vermont.
2001-2005	Chair, FAHC Trustee's Research Development Fund Scientific Review Committee and management of its annual \$500,000 award fund.
2001-2005	Member, Fletcher Allen Health Care Medical Staff Teaching and Research Committee.
2002	Chair, Search Committee for the UVM Physician Scientist Patient Oriented Research Scholars
2002-present	Member, Research, Scholarship and Creative Arts Committee of the University of Vermont Faculty Senate
2002-2003	Member, Search Committee for the UVM Vice President for Research and Dean of Graduate Studies
2003-2012	Chair, UVM Undergraduate Research Endeavors Competition Awards (URECA!) Review Committee
2003-present	Chair, Research, Scholarship and Creative Arts of the University of Vermont Faculty Senate

2003-present	Member, Executive Council of the University of Vermont Faculty Senate
2003-present	Member (Ex Officio), Graduate College Executive Committee, University of Vermont
2003-2005	Member, Intellectual Property Committee, University of Vermont
2003-present	Member, Scientific Conflict of Interest Committee, University of Vermont
2006-2008	Member, Research Advisory Board, University of Vermont
2007-2010	Member, UVM Innovations Fund Advisory Board
2007-2008	Member, UVM Planning Council
2008	Member, Search Committee for the Medicaid Medical Director of the State of Vermont
2008-2009	Member, UVM Emergency Management Planning Committee for Research
2008-2009	Chair, University Planning Council, Scholarship and Research Working Group
2008-2011	Member, Continuing Education Advisory Board
2009	Member, UVM Transformational Working Group
2009-2011	Member, Claims Data Release Advisory Committee for the Vermont Healthcare Claims Uniform Reporting and Evaluation System (VHCURES)
2009	Co-Chair, UVM Academic Quality Assurance Task Force
2009	Chair, Biological and Bioengineering Sciences Transdisciplinary Research Initiative Workgroup.
2009-2013	Member, Advisory Board of the Jeffords Center for Policy
2010-present	Member, Advisory Committee for the UVM Institute for Environmental Diplomacy and Security
2010-present	Senate Representative to the UVM Board of Trustees Educational Policy and Institutional Resources Committee
2011-2012	Co-Chair, Transdisciplinary Research Initiative Advisory Committee
2011-2012	Member, Transdisciplinary Research Initiative and Research Strategic Planning Committee
2012	Chair, Joint UVM/FAHC Data Policy and Privacy Committee
2012	Chair, LCME Self-study Sub-Committee V, College of Medicine, University of Vermont
2012	Chair, UVM Human Tissue Policy Committee

- 2013 Chair, UVM Graduate College Review Committee
- 2013 Member, Retired Faculty Scholarship Awards Review Committee

National and International Appointments:

- 1987-present Member, International Committee on the Review of the Porphyrinogenicity of Drugs
- 1988-present Board Member, The American Porphyria Foundation
- 1988-1994 Scientific Consultant, Glaxo, Inc., Research Triangle Park, North Carolina
- 1994-1996 Scientific Consultant, Parke-Davis Pharmaceutical Research (Warner-Lambert, Co.), Ann Arbor, MI
- 1994-1996 Scientific Consultant, Innovir Laboratories, New York, New York
- 1998-2001 Member, Executive Committee and Chair, Public Policy Subcommittee of the National GCRC Program Directors Association
- 2000-present Member, The Academic Health Centers Forum on Clinical Research and Member of the Public Policy Subcommittee
- 2001-2002 President, National GCRC Program Directors' Association
- 2001-2002 Member, Meeting Program Committee, Clinical Research 2002 and 2003
- 2001-2003 Member, NCRR Clinical Research Working Group, NIH
- 2001-2004 Scientific Consultant, MitoKor Pharmaceutical Corporation, CA
- 2003 Chair, Program Committee, Clinical Research 2004
- 2005-present Member, Clinical and Translational Research Subcommittee of the FASEB Science Policy Committee
- 2008-present Chair, Clinical and Translational Research Subcommittee of the FASEB Science Policy Committee
- 2010-2012 Member, Board of Directors of the Association for the Accreditation of Human Research Protection Programs.
- 2010-present Member, Research Information Subcommittee of the FASEB Science Policy Committee
- 2010 Chair, FASEB Symposium on the Engagement of Basic Scientists in Translational Research
- 2011-present Member, Clinical Research Forum Initiative with Patient Advocacy Groups Steering Committee

2011 Speaker at the First Annual U.S. National Academy - Russian Federation Scientific Forum Meeting, Moscow, Russia

2014-present Member, Research Enterprise Subcommittee of the FASEB Science Policy Committee

National External Advisory Committees for Clinical and Translational Research

Baylor College Children's Hospital, TX
Northwestern Medical School, IL
Stonybrook, New York University, NY
North Shore-Long Island Jewish Hospital System, NY
University of Pennsylvania, PA
University of Hawaii, HI
Maine Medical Center, ME
Dartmouth Medical School, NH
University of Connecticut, CT
New York University, NY
Howard University, DC
Columbia Presbyterian, NY
Rockefeller University, NY
University of Tennessee, TN
University of Massachusetts, MA
Pennsylvania State University, PA
Delaware University, DE

RESEARCH FUNDING:

Completed

Southern Medical Association (Galbraith) Insulin Receptors of Erythrocytes	06/18/79-05/01/80 \$1,000
Biomedical Research Support Grant (Galbraith) Medical University of South Carolina Insulin Receptor Homeostasis	08/01/80-07/31/81 \$12,255
American Diabetes Association (Galbraith) Effect of Amino Acids on Insulin Receptors	08/01/80-07/31/81 \$19,890
Juvenile Diabetes Foundation Fellowship (Galbraith) Evaluation of Insulin Binding and Response	07/01/80-06/30/82 \$45,000
Biomedical Research Support Grant (Galbraith) Medical University of South Carolina Insulin, Amino Acids and Insulin Receptors II	07/01/81-07/31/82 \$4,500
1 R23 AM29713 (Galbraith) NIAMDD Insulin, Amino Acids and Insulin Receptor Homeostasis	07/01/81-06/30/84 \$105,818

Hartford Foundation Fellowship (Galbraith) Insulin Receptor Regulation	06/01/82-05/31/85 \$118,400
Surdna Foundation Clinical Scholarship (Galbraith) Heme and Metalloporphyrins	07/01/86-06/30/91 \$125,000
Glaxo, Inc. (PI Kappas, Co-PI Galbraith) Heme Metabolism and Metalloporphyrins	06/06/88-06/05/94 \$3,000,000
M01 RR00102 (Galbraith: Program Director) NCRR General Clinical Research Center	12/01/93-11/31/98 \$31,125,494
Strang Cancer Prevention (Galbraith) Nutritional Effects on Carcinogens	07/01/93-06/30/94 \$29,000
M01 RR00109 (Galbraith: Program Director) NIH General Clinical Research Center	12/1/96-02/28/00 \$7,361,421
1S10RR13897-01 (Galbraith) NIH Shared Instrumentation Grant Program	04/01/99-09/30/00 \$236,500
P20 AR46667 (Galbraith; 10%) NIAMS Planning Grant for Multipurpose CRCs	09/29/99-03/30/02 \$99,730
M01 RR00109 (Galbraith: Program Director) NIH General Clinical Research Center	03/01/00-02/28/05 \$12,500,000
Burroughs Wellcome Fund/Robert Wood Johnson/ (Galbraith) Doris Duke Charitable Foundation/Damon Runyon- Walter Winchell Foundation/Juvenile Diabetes Foundation Funding to support the Clinical Research 2001 National Conjoint Meeting	1/1/01-12/31/01 \$167,000
Burroughs Wellcome Fund/Robert Wood Johnson/ (Galbraith) Doris Duke Charitable Foundation/Damon Runyon- Walter Winchell Foundation/Juvenile Diabetes Foundation Funding to support the Clinical Research 2002 National Conjoint Meeting.	1/1/02-12/31/02 \$147,000
MitoKor (Galbraith) Studies of Cobalt Protoporphyrin Derivatives	12/01/00-06/30/02 \$22,679
Burroughs Wellcome Fund/Robert Wood Johnson/ (Galbraith) Doris Duke Charitable Foundation/Howard Hughes/ Juvenile Diabetes Foundation Funding to support the	1/1/03-12/31/03 \$207,513

Clinical Research 2003 National Conjoint Meeting.

Burroughs Wellcome /Doris Duke / Howard Hughes/ Juvenile Diabetes/Robert Wood Johnson Foundations Clinical Research 2004 Meeting	11/01/03-10/31/04 \$117,000
Patient Oriented Research Pilot Award (Galbraith) UVM/Fletcher Allen Health Care Periodontitis: Local and Systemic Factors	11/01/03-10/31/05 \$20,000
R01 DK53479 (Galbraith) NIDDK Nutritional and Metabolic Regulation of Body Weight	09/30/99-08/31/08 \$1,242,433
R01 AG021106 Fukagawa (Galbraith: Co-I; 10%) NIH/NIA Age-Related Changes in Glutathione Synthesis	07/01/03-06/30/09 \$250,000
M01 RR00109 (Galbraith: Program Director; 50%) NCRR General Clinical Research Center	03/01/06-02/28/11 \$11,855,878

SOCIETY MEMBERSHIPS:

1977	Member, The Royal College of Physicians of the United Kingdom
1981	American Federation for Medical Research
1982	American College of Physicians
1988	National Association of GCRC Program Directors
1991	American College of Physician Executives
1991	The Royal Society of Medicine
1991	The American Society of Clinical Investigation
1992	Fellow, The Royal College of Physicians
1992	Member, The American Institute of Nutrition
1992	Member, The North American Society for the Study of Obesity
1992	Fellow, The American Society for Clinical Nutrition
1996	Member, Vermont Medical Society
1998	Member, Oxygen Society
1999	Founding Member, the Association for Patient-Oriented Research
2002	Member, Vermont Academy of Science and Engineering
2003	Member, Society for Experimental Biology and Medicine
2004	Member, Board of Governors of the Society for Experimental Biology and Medicine

BIBLIOGRAPHY

JOURNALS:

1. GALBRAITH, R.A., Evaluation of Health Care in an African Village. Environmental Child Health Journal, 22: 153, 1976.
2. GALBRAITH, R.A., Wise, W.C. and Buse, M.G. Insulin binding and response in erythroblastic leukemic cells. Diabetes, 29: 571-578, 1980.
3. GALBRAITH, R.A., Tucker, S., Wise, W.C. and Buse, M.G. Insulin binding to erythroblastic leukemia cells is decreased by insulin and increased by amino acids. Biochemical and Biophysical Research Communications, 96: 1434-1440, 1980.
4. Crouch, R.K., Gandy, S.E., Kimsey, G., GALBRAITH, R.A., Galbraith, G.M.P. and Buse, M.G. The inhibition of Islet Superoxide Dismutase by Diabetogenic Drugs. Diabetes, 30: 235-241, 1981.
5. GALBRAITH, R.A. Insulin receptor function and regulation in erythroblastic leukemic cells. Ph.D. Dissertation, 1981.
6. Gandy, S., GALBRAITH, R.A., Crouch, R.K., Buse, M.G. and Galbraith G.M.P. Superoxide dismutase in human islets of Langerhans. New England Journal of Medicine, 304: 1547-1548, 1981.
7. GALBRAITH, R.A. and Buse, M.G. Effects of serine on protein synthesis and insulin receptors. American Journal of Physiology, 241: C167-C171, 1981.
8. GALBRAITH, R.A., Spicer, S.S. and Buse, M.G. Rapid in vitro alterations in insulin binding: down-regulation with insulin and up-regulation with amino acids. Current Views on Insulin Receptors; Sero Symposium Series, Vol. 41, 385-395, 1982.
9. GALBRAITH, R.A., Buse, M.G. and Marchalonis, J.J. Insulin binding to cultured transformed B and T lymphocytes. Immunology Letters, 4: 141-144, 1982.
10. GALBRAITH, R.A. and Buse, M.G. Insulin receptor regulation. In Comparative Pathobiology, 15, Structure of Membranes, T.C. Chang (ed.), Plenum Press, pp. 17-31, 1984.
11. Buse, M.G., Cheema, I.R., Owens, M., Ledford, B.E. and GALBRAITH, R.A. Muscle protein synthesis: regulation of a translational inhibitor. American Journal of Physiology, 246: (Endocrinol. Metab. 9) E510-E515, 1984.
12. GALBRAITH, R.A. and Buse, M.G. Distribution of insulin receptors between plasmalemma and intracellular compartments: effect of amino acids. Journal of Cell Physiology, 122:120-124, 1985.
13. GALBRAITH, R.A. Sassa, S. and Kappas, A. Heme binding to murine erythroleukemia cells: Evidence for a heme receptor. Journal of Biology and Chemistry, 260: 12198-12202, 1985.
14. GALBRAITH, R.A., Drummond, G.S. and Kappas, A. Sn-protoporphyrin suppresses chemically induced experimental hepatic porphyria: Potential clinical implications. Journal of Clinical Investigation, 76: 2436-2439, 1985.

15. GALBRAITH, R.A. and Buse, M.G. The pleiotypic response to serine in erythroblastic leukemic cells. Hormone and Metabolic Research, 18: 173-176, 1986.
16. GALBRAITH, R.A., Sassa, S. and Kappas, A. Induction of haem synthesis in Hep G2 human hepatoma cells by dimethyl sulphoxide: A transcriptionally activated event. Biochemistry Journal, 237: 597-600, 1986.
17. GALBRAITH, R.A., Drummond, G.S., Krey, L. and Kappas, A. The relationship of suppression of the androgenic axis by cobalt-protoporphyrin to its effects on weight loss and hepatic heme oxygenase induction. Pharmacology, 34: 241-249, 1987.
18. Sassa, S., Sugita, O., GALBRAITH, R.A. and Kappas, A. Drug metabolism by the human hepatoma cell, Hep G2. Biochemical and Biophysical Research Communication, 143: 52-57, 1987.
19. Drummond, G.S., GALBRAITH, R.A., Sardana, M.K., and Kappas, A. Reduction of the C2 and C4 vinyl groups of Sn-protoporphyrin to form Sn-mesoporphyrin markedly enhances the ability of the metalloporphyrin to inhibit *in vivo* heme catabolism. Archives of Biochemistry and Biophysiology, 255: 64-74, 1987.
20. GALBRAITH, R.A., Sassa, S. and Kappas, A. A comparison of the utility of Dowex resin and polybenzimidazole Aurerez resin in the determination of urinary porphobilinogen concentrations. Clinica Chimica Acta., 164: 235-239, 1987.
21. GALBRAITH, R.A. and Jellinck, P.H. Cobalt-protoporphyrin causes prolonged inhibition of catechol estrogen synthesis by rat liver microsomes. Biochemical and Biophysical Research Communications, 145: 376-383, 1987.
22. Tate, S.S. and GALBRAITH, R.A. A Human-Hepatoma cell line expresses a single-chain form of γ -glutamyl transpeptidase. Journal of Biological Chemistry, 262: 11403-11406, 1987.
23. GALBRAITH, R.A. Hormonal regulation of the heme pathway. Annals of the New York Academy of Sciences., 514: 256-260, 1988.
24. Wissel, P.S., GALBRAITH, R.A., Sassa, S. and Kappas, A. Tin-protoporphyrin inhibits heme oxygenase and prevents the decline in hepatic heme and cytochrome P-450 contents produced in nude mice by tumor transplantation. Biochemical and Biophysical Research Communications, 150: 822-827, 1988.
25. GALBRAITH, R.A. and McElrath, M.J. Heme binding to *Leishmania mexicana amazonensis*. Molecular and Biochemical Parasitology, 29: 47-54, 1988.
26. GALBRAITH, R.A., Sassa, S. and Fujita, H. Regulation of heme synthesis in Hep G2 human hepatoma cells by dimethylsulfoxide. Biochemical and Biophysical Research Communications, 153: 869-874, 1988.
27. Iwasa, F., GALBRAITH, R.A. and Sassa, S. Effects of dimethylsulfoxide on the synthesis of plasma proteins in the human hepatoma Hep G2: Induction of an acute phase-like reaction. Biochemical Journal, 253: 927-930, 1988.
28. Tate, S.S. and GALBRAITH, R.A. In vitro translation and processing of human hepatoma cell (Hep G2) γ -glutamyl transpeptidase. Biochemical and Biophysical Research Communications, 154: 1167-

- 1173, 1988.
29. Simionatto, C.S., Cabal, R., Jones, R.L. and GALBRAITH, R.A. Thrombophlebitis and disturbed hemostasis following intravenous hematin in normal volunteers. American Journal of Medicine, 85: 538-540, 1988.
 30. Kappas, A., Sassa, S., GALBRAITH, R.A. and Nordman, Y. The Porphyrins, in The Metabolic Basis of Inherited Diseases, VI Edition, Ed. Scriver, C.R., Beaudet, A.L., Sly, W.S. and Valle, D. McGraw-Hill, New York, 1305-1365, 1989.
 31. GALBRAITH, R.A. and Jellinck, P.H. Decreased estrogen hydroxylation in male rat liver following cimetidine treatment. Biochemical Pharmacology, 38: 313-319, 1989.
 32. GALBRAITH, R.A. and Jellinck, P.H. Cobalt-protoporphyrin, a synthetic heme analogue, feminizes hepatic androgen metabolism in the rat. Journal of Steroid Biochemistry and Molecular Biology, 32: 421-426, 1989.
 33. GALBRAITH, R.A. and Kappas, A. Pharmacokinetics of tin-mesoporphyrin in man and the effects of tin-chelated porphyrins on hyperexcretion of heme pathway precursors in patients with acute inducible porphyria. Hepatology, 9: 882-888, 1989.
 34. GALBRAITH, R.A. and Jellinck, P.H. Differential effects of cimetidine, ranitidine and famotidine on the hepatic metabolism of estrogen and testosterone in male rats. Biochemical Pharmacology, 38: 2046-2049, 1989.
 35. GALBRAITH, R.A. and Krey, L. Cobalt-protoporphyrin suppresses testosterone secretions by multiple interactions within the brain-pituitary-testicular axis. Neuroendocrinology, 49: 641-648, 1989.
 36. GALBRAITH, R.A. and Michnovicz, J.J. The effects of cimetidine on the oxidative metabolism of estradiol. New England Journal of Medicine, 32: 269-274, 1989.
 37. GALBRAITH, R.A. and Kappas, A. Regulation of food intake and body weight by cobalt-porphyrins in animals. Proceedings of the National Academy of Sciences, USA, 86: 7653-7657, 1989.
 38. GALBRAITH, R.A. and Michnovicz, J.J. The oxidative metabolism of estradiol; inhibition by cimetidine. Transactions Association of American Physicians, 102: 44-54, 1989.
 39. Michnovicz, J.J. and GALBRAITH, R.A. Effects of exogenous thyroxine on C-2 and C-16 α hydroxylations of estradiol in humans. Steroids, 55: 22-26, 1990.
 40. Iwasa, F., GALBRAITH, R.A. and Sassa, S. Phenotypic variation in human Hep G2 hepatoma cells: Alterations in cell growth, plasma protein synthesis and heme pathway enzymes. International Journal of Biochemistry, 22: 303-310, 1990.
 41. GALBRAITH, R.A., Sassa, S. and Kappas, A. Porphyria, in Hematologic Disorders in Maternal-Fetal Medicine Bern, M.M. and Frigoletto, F.D. (eds.) Wiley-Liss and Sons, Inc., New York, pp. 249-260, 1990.
 42. Sassa, S., Iwasa, F. and GALBRAITH, R.A. The effect of DMSO on heme biosynthesis and the

- acute phase reaction in Hep G2 human hepatoma cells, in The Molecular Biology of Erythropoiesis; Advances in Experimental Medicine and Biology, Vol. 271. J.L. Ascensao, E.D. Zanjani, M. Tauassoli, A.S. Levine and F.R. MacKintosh (eds.), Plenum Press, New York, pp. 103-114, 1990.
43. GALBRAITH, R.A. The Porphyrins, in Inherited Metabolic Disease: Diagnosis and Treatment. Fernandes, J., Saudubray, J.M. and K. Tada (eds.), Springer-Verlag, Berlin, 477-489, 1990.
 44. GALBRAITH, R.A. Heme binding to Hep G2 human hepatoma cells. Journal of Hepatology, 10: 305-310, 1990.
 45. GALBRAITH, R.A. and Kappas, A. Cobalt-protoporphyrin suppresses expression of genetic obesity in homozygous (fa/fa) Zucker rates. Pharmacology, 41: 292-298, 1990.
 46. GALBRAITH, R.A. and Jellinck, P.H. Selective inhibition of cytochrome P450 in rat testicular microsomes: effect of cobalt-protoporphyrin on progesterone metabolism. Journal of Steroid Biochemistry and Molecular Biology, 36 563-568, 1990.
 47. Soloman, G., Labar, D., GALBRAITH, R.A., Schaefer, J. and Kappas, A. Neurophysiological abnormalities in adolescents with type I Crigler-Najjar Syndrome. Electroencephalography and Clinical Neurophysiology, 76: 473-475, 1990.
 48. GALBRAITH, R.A. Sexual side effects of drugs. Drug Therapy, 21: 38-45, 1990.
 49. Michnovicz, J.J. and GALBRAITH, R.A. Cimetidine inhibits catechol estrogen metabolism in women. Metabolism, 40: 170-174, 1991.
 50. GALBRAITH, R.A. Intermediary metabolism in Leishmania. Journal of Nutritional Biochemistry, 2: 180-184, 1991.
 51. GALBRAITH, R.A. and Kappas, A. Cobalt protoporphyrin regulates body weight in Beagle dogs: Induction of weight loss in normal animals of stable adult weight. Pharmacology, 43: 96-105, 1991.
 52. GALBRAITH, R.A. and Jellinck, P.H. Omeprazole and cytochrome P450-dependent hepatic metabolism; a comparison of endogenous and exogenous substrates in male rats. Pharmacology, 42: 322-326, 1991.
 53. GALBRAITH, R.A. and Kappas, A. The effects of cobalt-protoporphyrin on food intake, body weight and metabolism in adult male rats. American Journal of Physiology, 261: (Regulatory Integrative Comp. Physiol.30) R1288-R1394, 1991.
 54. GALBRAITH, R.A. and Kappas, A. Intracerebroventricular administration of cobalt protoporphyrin elicits prolonged weight reduction in rats. American Journal of Physiology, 261: (Regulatory Integrative Comp. Physiol.30) R1395-R1401, 1991.
 55. Jellinck, P.H. and GALBRAITH, R.A. Suppression of 5 α -androstane-3 β -diol hydroxylase activity in rat pituitary by cobalt protoporphyrin: implications for testosterone homeostasis. Journal of Steroid Biochemistry and Molecular Biology, 39: 947-951, 1991.
 56. GALBRAITH, R.A. Porphyria, in Conn's Current Therapy; Robert Rakel (ed.), W.B. Saunders Co., Philadelphia, PA, 390-393, 1992.

57. GALBRAITH, R.A., Drummond, G.S. and Kappas, A. Suppression of bilirubin production in the Crigler-Najjar Type 1 Syndrome: Studies with the heme oxygenase inhibitor Tin-mesoporphyrin. Pediatrics, 89: 175-182, 1992.
58. GALBRAITH, R.A., Kow, L-M., Pfaff, D. and Kappas, A. Injection of cobalt protoporphyrin into the medical nuclei of the hypothalamus elicits weight loss. American Journal of Physiology, 263 (Regulatory Integrative Comp. Physiol. 32): R805-R812, 1992.
59. GALBRAITH, R.A., Chua, S.C. and Kappas, A. Hypothalamic mechanism for cobalt protoporphyrin-induced hypophagia and weight loss: inhibition of the feeding response to NPY. Molecular Brain Research, 15: 298-302, 1992.
60. GALBRAITH, R.A. and Michnovicz, J. Omeprazole fails to alter the cytochrome P450-dependent metabolism of estradiol in men. Pharmacology, 47: 8-12, 1993.
61. Kappas, A., Drummond, G.S. and GALBRAITH, R.A. Prolonged clinical use of a heme oxygenase inhibitor: hematological evidence for an inducible but reversible iron-deficiency state. Pediatrics, 91: 537-539, 1993.
62. Boni, R.E., Boni, R.A.H., GALBRAITH, R.A., Drummond, G.S. and Kappas, A. Tin-mesoporphyrin inhibits heme oxygenase activity and heme-iron absorption in the intestine. Pharmacology, 47: 318-329, 1993.
63. Lenny, L.L., Hurst, R., Goldstein, J. and GALBRAITH, R.A. Two-unit transfusions to Group O subjects of red blood cells enzymatically converted from Group B to Group O. Transfusion, 34: 209-214, 1994.
64. Meguro, K., Fujita, H., Ishida, N., Akagi, R., Kurihara, T., GALBRAITH, R.A., Zabriskie, J.B., Toback, A.C., Harber, L.C., and Sassa, S. The Molecular Defects of Uroporphyrinogen Decarboxylase in a Patient with Mild Hepatoerythropoietic Porphyria. Journal of Investigative Dermatology, 102: 681-685, 1994.
65. Turner, M.B., Corp, E.S. and GALBRAITH, R.A. Lack of NPY-induced feeding in cobalt-protoporphyrin-treated rats is a post-receptor defect. Physiology and Behaviour, 56: 1009-1014, 1994.
66. Kappas, A., Sassa, S., GALBRAITH, R.A. and Nordman, Y. Porphyria in "The Metabolic Basis of Inherited Disease" VII Edition, 1995.
67. Mercurio, M., Shiff, S., GALBRAITH, R.A. and Sassa, S. Expression of cytochrome P450 mRNAs in the colon and the rectum in normal human subjects. Biochemical & Biophysical Research Communications, 210: 350-355, 1995.
68. Lenny, L.L., Hurst, R., Zhu, A., Goldstein, J. and GALBRAITH, R.A. Multi-unit and second transfusions of red cells enzymatically converted from group B to group O: End of Phase 1 trials report. Transfusions, 35: 899-902, 1995.
69. Takle, G., Thierry, A., Flynn, S., Peng, B., White, L., Devonish, W., GALBRAITH, R., Goldberg, A. and George, S. Delivery of oligoribonucleotides to human hepatoma cells using cationic lipid particles conjugated to ferric protoporphyrin IX (heme). Antisense and Nucleic Acid Drug

- Development, 7: 177-185, 1997.
70. Sassa, S., Kondo, M., Taketani, S., Nomura, N., Furuyama, K., Akagi, R., Nagai, T., Terajima, M., GALBRAITH, R. and Fujita, H. Molecular defects of the coproporphyrinogen oxidase gene in hereditary coproporphyrin. Cellular and Molecular Biology, 43(1): 59-66, 1997.
 71. GALBRAITH, R. and Sobel, B. Patient Information and confidentiality: a compelling conundrum. Journal of Coronary Artery Disease, 8(1): 59-60, 1997.
 72. Berglund, L., GALBRAITH, R.A., Emtestam, L., Drummond, G.S., Angelin, B., Kappas, A. Heme oxygenase inhibitors transiently increased serum ferritin concentrations without altering other acute-phase reactants in man. Pharmacology, 59: 51-56, 1999.
 73. GALBRAITH, R.A. Heme oxygenase: Who needs it? Proceedings of the Society for Experimental Biology and Medicine, 222(3):299-305, 1999.
 74. Fukagawa, N.K. and GALBRAITH, R.A. Advancing Age and Factors Influencing the Balance Between Amino Acid Requirements and Toxicity . Journal of Nutrition, 134: 1569S-1574S, 2004.
 75. GALBRAITH, R.A., Hodgdon, I., Grimm, M.S. and Vizzard, M. A. Prolonged Retention of the Anorectic Cobalt Protoporphyrin in the Hypothalamus and the Resulting Expression of Fos. American Journal of Physiology, Regulatory Integrative Comparative Physiology, 287: R465-R471,2004.
 76. Li, M., Vizzard, M.A., Jaworski, D and GALBRAITH, R.A. The Weight Loss Elicited by Cobalt Protoporphyrin is related to decreased activity of nitric oxide synthase in the hypothalamus. The Journal of Applied Physiology, 100:1983-1991, 2006.
 77. GALBRAITH, R.A., Furukawa, M. and Li, M. Possible role of creatine concentrations in the brain in regulating appetite and body weight. Brain Research, 1101: 85-91, 2006.
 78. Hobin, J.A., Deschamps, A.M., Bockman, R., Cohen, S., Dechow, P., Eng, C., Galey, W., Morris, M., Prabhakar, S., Raj, U., Rubenstein, P., Smith, J.A., Stover, P., Sung, N., Talman, W. and GALBRAITH, R. Engaging basic scientists in translational research identifying opportunities, overcoming obstacles. Journal of Translational Medicine, Apr 13;10(1):72, 2012. Published online 2012 April 13. doi: 10.1186/1479-5876-10-72.
 79. Hobin, J.A. and GALBRAITH, R.A. Engaging basic scientists in translational research. The FASEB Journal, Jun;26(6):2227-2230, 2012.
 80. Bond, J.S. and GALBRAITH, R.A. The Challenge of engaging basic scientists in translational research. The AAMC Reporter, Dec 2012.
 81. Gallin, E.K., Bond, E., Califf, R., Crowley, W.F., Davis, P., GALBRAITH, R., Reece, E.A. Forging stronger partnerships between academic health centers and patient-driven organizations. Academic Medicine 2013 88(9): 1220-1224.
 82. Jones, C.A., Callas, P.W., Everett, R.W., GALBRAITH, R.A., Spitsberg, R., Petrozzino, J.J., DeSarno, M.J., Stanley, A.C. An algorithm to analyze cost heterogeneity using counterfactual scenarios in endovascular versus open repair of abdominal aortic aneurysm (AAA): Predicting costs for subsequent patients. Journal of Health Economics and Outcomes Research, in press.

BOOKS:

1. Galbraith, R.A. Board of Medical Consultants. In The PDR Family Guide to Nutrition and Health, Montvale, NJ: Medical Economics, 1995.
2. Galbraith, R.A. Chairperson, Board of Medical Consultants. In The PDR Family Guide to Natural Medicines & Healing Therapies, Montvale, NJ: Medical Economics, 1999.